Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002232818 | SCV000812361 | pathogenic | Hereditary hemorrhagic telangiectasia | 2025-01-19 | criteria provided, single submitter | clinical testing | This sequence change replaces leucine, which is neutral and non-polar, with proline, which is neutral and non-polar, at codon 8 of the ENG protein (p.Leu8Pro). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individuals with hereditary hemorrhagic telangiectasia (PMID: 15024723, 19767588). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 565357). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt ENG protein function with a negative predictive value of 95%. For these reasons, this variant has been classified as Pathogenic. |
Ambry Genetics | RCV002442411 | SCV002732565 | pathogenic | Cardiovascular phenotype | 2022-11-22 | criteria provided, single submitter | clinical testing | The p.L8P pathogenic mutation (also known as c.23T>C), located in coding exon 1 of the ENG gene, results from a T to C substitution at nucleotide position 23. The leucine at codon 8 is replaced by proline, an amino acid with similar properties. This mutation has been reported in multiple individuals with hereditary hemorrhagic telangiectasia (HHT) and has shown strong segregation with disease (Lesca G et al. Hum. Mutat., 2004 Apr;23:289-99; McDonald J et al. J Mol Diagn, 2009 Nov;11:569-75). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. |
Mayo Clinic Laboratories, |
RCV004792371 | SCV005413918 | likely pathogenic | not provided | 2024-07-25 | criteria provided, single submitter | clinical testing | BP4_strong, PP1_strong, PP4, PM2, PS4_moderate |